In (1) the reallocated population are 43 patients: 19 patients in the almotriptan 12.5 mg and 22 in the placebo allocation for the treat when mild pain group, who treated the migraine attack when pain intensity became moderate or severe; and 2 patients of the almotriptan 12.5 moderate-severe intensity group who treated pain of mild intensity. (see figure 1, page 386).
This means on page 386, in AwM section line 6, ‘. . . , 38 subjects assigned to treat a mild pain had missed the correct timing. . . .’ should read ‘. . . , 41 subjects assigned to treat a mild pain had missed the correct timing. . . .’.
Furthermore, on page 386, in AwM section, line 12, 53% (46/86) of patients of the AwM population in the almotriptan 12.5 mg group were pain free by 2 h and not 54% as written in the text.
We apologise for these errors.